system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Cross-Over Studies, ErbB Receptors, Erlotinib Hydrochloride, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Mutation, Neoplasm Proteins, Pancreatic Neoplasms, Prognosis, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), Quinazolines, Treatment Outcome, ras Proteins.
user
Is kRAS mutation status predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer? Context: It has not yet been defined if KRAS has a prognostic value or is a predictive biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC). AIO-PK0104 was a phase III trial comparing gemcitabine/erlotinib followed by capecitabine with capecitabine/erlotinib followed by gemcitabine in advanced PC. For this post hoc subgroup analysis, biomarker data on the KRAS exon 2 mutation status were correlated with objective response to 1st-line therapy and with overall survival after start of 2nd-line chemotherapy (OSc). KRAS codon 12 was mutated in 121 of 173 (70 %) patients. The KRAS status showed no association with objective response (p = 0.40), but KRAS wildtype patients had an improved OS (HR 1.68, p = 0.005). A trend for a survival benefit was also observed during (non-erlotinib containing) 2nd-line chemotherapy, with a HR of 1.47 (p = 0.10) for the OSc.
assistant
This post hoc analysis of AIO-PK0104 supports the assumption that KRAS is rather a prognostic than a predictive biomarker in PC. Final Decision: no